Biomarin Pharmaceutical Inc
(NAS:BMRN)
$
66.24
0.11 (0.17%)
Market Cap: 12.62 Bil
Enterprise Value: 12.27 Bil
PE Ratio: 39.66
PB Ratio: 2.33
GF Score: 67/100 Biomarin Pharmaceutical Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 19, 2021 / 03:30PM GMT
Release Date Price:
$76.42
(-1.61%)
Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research
Hi. My name is Kennen MacKay. I'm one of the biotechnology analysts here at RBC, and it's my great pleasure to kick off our last session of the morning with BioMarin Pharmaceuticals. From BioMarin, we have Brian Mueller, Executive Vice President and Chief Financial Officer; as well as Hank Fuchs, President of Worldwide Research & Development. With that, I turn it over to you.
Questions & Answers
Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research
You're keeping me on my toes this morning with a little bit of news out of the -- a lot of bit of news out of the Valrox program. Maybe you can talk a little bit about that and just give sort of a brief background of where we are.
Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development
Sure thing. Good morning. Thank you, Kennen, for the introduction, and good
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot